title: Targeting bone physiology for the treatment of metastatic prostate cancer.
abstract: Metastatic prostate cancer has a unique predilection for bone that can lead to significant clinical sequelae, such as fracture and cord compression. This tropism for bone yields not only clinical challenges, but also opportunities to understand the tumor biology in bone and to develop relevant therapeutic strategies. The process by which tumor cells migrate to bone, remain dormant, and then colonize and expand is based on complex interactions between prostate cancer tumor cells and the host microenvironment. This review will provide an overview of these interactions as well as therapies targeting osseous metastases in castration-resistant prostate cancer.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Karen A
authors.initials: KA
authors.lastname: Autio
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Morris
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D001862:Bone Resorption / Q000188:drug therapy / Q000532:radiotherapy; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology*; D002471:Cell Transformation, Neoplastic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008297:Male; D010010:Osteoclasts / Q000187:drug effects / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D019275:Radiopharmaceuticals / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals